1887

Abstract

The in vitro activity of anti-pseudomonal β-lactams in combination with avibactam was evaluated against 54 multidrug-resistant non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients. Avibactam increased and/or restored the antibacterial activities of ceftazidime and aztreonam against Pseudomonas aeruginosa and Stenotrophomonas maltophilia, respectively. No β-lactam–avibactam combination was active against Achromobacter xylosoxidans.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000801
2018-07-17
2020-09-30
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/9/1217.html?itemId=/content/journal/jmm/10.1099/jmm.0.000801&mimeType=html&fmt=ahah

References

  1. Elborn JS. Cystic fibrosis. The Lancet 2016;388:2519–2531 [CrossRef]
    [Google Scholar]
  2. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL et al. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med 2009;180:802–808 [CrossRef]
    [Google Scholar]
  3. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E et al. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013;12:482–486 [CrossRef][PubMed]
    [Google Scholar]
  4. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018;17:153–178 [CrossRef][PubMed]
    [Google Scholar]
  5. Edwards BD, Greysson-Wong J, Somayaji R, Waddell B, Whelan FJ et al. Prevalence and outcomes of Achromobacter species infections in adults with cystic fibrosis: a North American cohort study. J Clin Microbiol 2017;55:2074–2085 [CrossRef][PubMed]
    [Google Scholar]
  6. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006;73:27–33 [CrossRef][PubMed]
    [Google Scholar]
  7. Stefani S, Campana S, Cariani L, Carnovale V, Colombo C et al. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Int J Med Microbiol 2017;307:353–362 [CrossRef][PubMed]
    [Google Scholar]
  8. Burgel PR, Bellis G, Olesen HV, Viviani L, Zolin A et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015;46:133–141 [CrossRef][PubMed]
    [Google Scholar]
  9. Spencker FB, Staber L, Lietz T, Schille R, Rodloff AC. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin Microbiol Infect 2003;9:370–379 [CrossRef][PubMed]
    [Google Scholar]
  10. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Høiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother 1990;26:247–259 [CrossRef][PubMed]
    [Google Scholar]
  11. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993;31:919–926 [CrossRef][PubMed]
    [Google Scholar]
  12. Llanes C, Pourcel C, Richardot C, Plésiat P, Fichant G et al. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. J Antimicrob Chemother 2013;68:1763–1771 [CrossRef][PubMed]
    [Google Scholar]
  13. Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA 2012;109:11663–11668 [CrossRef][PubMed]
    [Google Scholar]
  14. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018;18:285–295 [CrossRef][PubMed]
    [Google Scholar]
  15. Santevecchi BA, Smith TT, MacVane SH. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae. Int J Antimicrob Agents 2018;51:629–635 [CrossRef][PubMed]
    [Google Scholar]
  16. Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother 2015;70:1596–1598 [CrossRef][PubMed]
    [Google Scholar]
  17. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010;65:2376–2381 [CrossRef][PubMed]
    [Google Scholar]
  18. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A et al. Efflux pumps, OprD porin, AmpC β-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2010;54:2219–2224 [CrossRef][PubMed]
    [Google Scholar]
  19. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 2002;34:634–640 [CrossRef][PubMed]
    [Google Scholar]
  20. Grohs P, Taieb G, Morand P, Kaibi I, Podglajen I et al. In vitro activity of ceftolozane-tazobactam against multidrug-resistant nonfermenting gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2017;61:e02688-16 [CrossRef][PubMed]
    [Google Scholar]
  21. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID) EUCAST definitive document E.DEF 3.1, June 2000: determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 2000;6:509–515[PubMed]
    [Google Scholar]
  22. Mojica MF, Papp-Wallace KM, Taracila MA, Barnes MD, Rutter JD et al. Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam. Antimicrob Agents Chemother 2017;61:e00777-17 [CrossRef][PubMed]
    [Google Scholar]
  23. Bador J, Amoureux L, Duez JM, Drabowicz A, Siebor E et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother 2011;55:4912–4914 [CrossRef][PubMed]
    [Google Scholar]
  24. Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother 2016;60:5130–5134 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000801
Loading
/content/journal/jmm/10.1099/jmm.0.000801
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error